Cognition Therapeutics (CGTX) Change in Accured Expenses (2020 - 2026)
Cognition Therapeutics (CGTX) reported Change in Accured Expenses of -$7.6 million for Q1 2026, down 9993.33% year-over-year from N/an in Q1 2025, and down 189.97% on a QoQ basis from $8.4 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Change in Accured Expenses data on file, last reported at -$7.6 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 9993.33% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 284.83% YoY) and the FY2025 annual result came in at $3.5 million, up 89.32% from the prior year.
- Change in Accured Expenses slipped to -$7.6 million in Q1 2026 per CGTX's latest filing, from $8.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $8.4 million in Q4 2025 and bottomed at -$7.6 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is -$75000.0 (2023), against an average of -$30294.1.
- The widest annual swing landed in 2022, when Change in Accured Expenses soared 611.3%; it then plunged 9993.33% in 2026.
- Tracing CGTX's Change in Accured Expenses over 5 years: stood at -$5.2 million in 2022, then soared by 111.53% to $603000.0 in 2023, then tumbled by 397.84% to -$1.8 million in 2024, then surged by 568.49% to $8.4 million in 2025, then slumped by 189.97% to -$7.6 million in 2026.
- Per Business Quant, the three latest CGTX Change in Accured Expenses figures stand at -$7.6 million (Q1 2026), $8.4 million (Q4 2025), and -$5.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -7.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.57 Mn |
| Mar 31, 2026 | -7.57 Mn |
| Dec 31, 2025 | 8.41 Mn |
| Dec 31, 2025 | 8.41 Mn |
| Sep 30, 2025 | -5.44 Mn |
| Sep 30, 2025 | -5.44 Mn |
| Jun 30, 2025 | 614,000.00 |
| Jun 30, 2025 | 614,000.00 |
| Mar 31, 2025 | -75,000.00 |
| Mar 31, 2025 | -75,000.00 |
| Dec 31, 2024 | -1.80 Mn |
| Dec 31, 2024 | -1.80 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | -377,000.00 |
| Mar 31, 2024 | -377,000.00 |
| Dec 31, 2023 | 603,000.00 |
| Dec 31, 2023 | 603,000.00 |
| Sep 30, 2023 | 672,000.00 |
| Sep 30, 2023 | 672,000.00 |
| Jun 30, 2023 | 1.24 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | -75,000.00 |
| Mar 31, 2023 | -75,000.00 |
| Dec 31, 2022 | -5.23 Mn |
| Dec 31, 2022 | -5.23 Mn |
| Sep 30, 2022 | 5.43 Mn |
| Sep 30, 2022 | 5.43 Mn |
| Jun 30, 2022 | -409,000.00 |
| Jun 30, 2022 | -409,000.00 |
| Mar 31, 2022 | -539,000.00 |
| Mar 31, 2022 | -539,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | -1.06 Mn |
| Sep 30, 2021 | -1.06 Mn |
| Jun 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 1.57 Mn |
| Mar 31, 2021 | -253,000.00 |
| Mar 31, 2021 | -253,000.00 |
| Dec 31, 2020 | -23,000.00 |
| Dec 31, 2020 | -23,000.00 |